TransCode Therapeutics Inc (RNAZ) concluded trading on Wednesday at a closing price of $1.02, with 10.36 million shares of worth about $10.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -87.91% during that period and on March 12, 2025 the price saw a loss of about -8.93%. Currently the company’s common shares owned by public are about 0.70M shares, out of which, 0.66M shares are available for trading.
Stock saw a price change of -44.26% in past 5 days and over the past one month there was a price change of -91.36%. Year-to-date (YTD), RNAZ shares are showing a performance of -69.73% which decreased to -95.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.10 but also hit the highest price of $66.33 during that period. The average intraday trading volume for TransCode Therapeutics Inc shares is 1.91 million. The stock is currently trading -79.82% below its 20-day simple moving average (SMA20), while that difference is down -81.53% for SMA50 and it goes to -93.40% lower than SMA200.
TransCode Therapeutics Inc (NASDAQ: RNAZ) currently have 0.70M outstanding shares and institutions hold larger chunk of about 26.18% of that.
The stock has a current market capitalization of $0.71M and its 3Y-monthly beta is at 1.33. It has posted earnings per share of -$265.83 in the same period. It has Quick Ratio of 1.58 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNAZ, volatility over the week remained 17.50% while standing at 21.83% over the month.
Stock’s fiscal year EPS is expected to rise by 95.41% while it is estimated to increase by 8.19% in next year. EPS is likely to grow at an annualized rate of 78.85% for next 5-years, compared to annual growth of -28.81% made by the stock over the past 5-years.
